StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)

Close on Nov 17, 2026Market cap $253.10MP/E –Yield –

Enanta Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Enanta Pharmaceuticals's price to book ratio was 3.3× on Nov 11, 2026, against 4.7× a year earlier. Over the last 5 years it ranged from 0.8× to 5.2×, with a median of 2.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.3×−1.9
2025Dec 31, 20255.2×+4.3
2024Dec 31, 20241.0×+0.0
2023Dec 29, 20230.9×−2.1
2022Dec 30, 20223.0×−0.8
2021Dec 31, 20213.8×+1.9
2020Dec 31, 20201.9×−0.8
2019Dec 31, 20192.6×−0.9
2018Dec 31, 20183.5×−0.2
2017Dec 29, 20173.7×+1.4
2016Dec 30, 20162.4×−0.3
2015Dec 31, 20152.6×−3.7
2014Dec 31, 20146.4×+1.9
2013Dec 31, 20134.4×–

More Enanta Pharmaceuticals figures

See a number that looks wrong?